Category Archives: Top Market News

Jefferies Believes Check Point (NASDAQ: CHKP) Still Has Room to Grow

Jefferies analyst John Difucci reiterated a Buy rating on Check Point (NASDAQ: CHKP) today and set a price target of $126. The company’s shares closed yesterday at $118.01, close to its 52-week high of $119.20. According to TipRanks.com, Difucci is

Jefferies Believes RingCentral (NYSE: RNG) Won’t Stop Here

In a report released today, John Difucci from Jefferies reiterated a Buy rating on RingCentral (NYSE: RNG), with a price target of $48. The company’s shares closed yesterday at $41.35, close to its 52-week high of $44.95. According to TipRanks.com,

Repligen Corp Receives a Rating Update from a Top Analyst

In a report released yesterday, Brandon Couillard from Jefferies reiterated a Hold rating on Repligen Corp (NASDAQ: RGEN), with a price target of $40. The company’s shares closed yesterday at $36.27. According to TipRanks.com, Couillard is a top 100 analyst

Enzymotec Gets a Hold Rating from Jefferies

Jefferies analyst Laurence Alexander reiterated a Hold rating on Enzymotec (NASDAQ: ENZY) on October 17 and set a price target of $11.50. The company’s shares closed yesterday at $11.15. According to TipRanks.com, Alexander is a top 25 analyst with an

Analysts Offer Insights on Healthcare Companies: Abbott Labs (NYSE: ABT), China Biologic (NASDAQ: CBPO) and Insys Therapeutics (NASDAQ: INSY)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Abbott Labs (NYSE: ABT), China Biologic (NASDAQ: CBPO) and Insys Therapeutics (NASDAQ: INSY) with bullish sentiments. Abbott Labs (NYSE: ABT) Jefferies analyst

B. Riley Believes Limelight Networks (NASDAQ: LLNW) Won’t Stop Here

B. Riley analyst Sameet Sinha reiterated a Buy rating on Limelight Networks (NASDAQ: LLNW) today and set a price target of $6. The company’s shares closed yesterday at $4.48, close to its 52-week high of $4.52. Sinha commented: “We have